Recent Insider Transactions • Jul 17
Executive Chairperson recently bought CA$88k worth of stock On the 14th of July, Alan Simpson bought around 173k shares on-market at roughly CA$0.51 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Alan has been a buyer over the last 12 months, purchasing a net total of CA$1.1m worth in shares. Ankündigung • Jul 14
PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 10.00008 million. PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 10.00008 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 19,608,000
Price\Range: CAD 0.51
Discount Per Security: CAD 0.0306 Ankündigung • Jul 07
PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million. PharmaCorp Rx Inc. (TSXV:PCRX) entered into definitive share purchase agreement to acquire Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on April 28, 2026. A cash consideration of CAD 24.2 million will be paid by PharmaCorp Rx Inc. subject to customary adjustments. As part of consideration, CAD 24.2 million is paid towards interests of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada. The consideration is expected to be funded using the Corporation’s existing cash resources. In addition, the Corporation has also entered into non-binding letters of intent (“LOIs”) in respect of four additional pharmacy acquisitions.
All locations will continue to be operated by their existing managing pharmacists, ensuring continuity of care, preserving patient relationships, and supporting a seamless transition and integration into the PharmaCorp platform.
The transaction is subject to customary closing conditions. The Transaction is expected to close within 60 days.
PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on July 6, 2026. Reported Earnings • May 05
Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024) Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 30
Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024) Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024). Ankündigung • Nov 29
PharmaCorp Rx Inc. Announces Management Changes Pharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures. New Risk • Nov 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m). Buy Or Sell Opportunity • Nov 21
Now 24% overvalued Over the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%. Recent Insider Transactions • Nov 16
Executive Chairperson recently bought CA$1.0m worth of stock On the 12th of November, Alan Simpson bought around 2m shares on-market at roughly CA$0.42 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months. Ankündigung • Nov 13
PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million. PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 47,700,000
Price\Range: CAD 0.42
Discount Per Security: CAD 0.0252 Ankündigung • Aug 25
PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025 PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025. Reported Earnings • Aug 18
Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024) Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024). Ankündigung • Aug 08
PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc. PharmaCorp Rx Inc. (TSXV:PCRX) entered into share purchase agreement to acquire Pharmacy business from PharmaChoice Canada Inc. for CAD 2.4 million on June 24, 2025. The purchase price is subject to customary adjustments which will be paid using cash on hand.
The Acquisition is expected to close on or about July 31, 2025, subject to satisfaction of customary closing conditions.
PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc on August 7, 2025. Buy Or Sell Opportunity • Jul 30
Now 24% overvalued Over the last 90 days, the stock has fallen 4.1% to CA$0.47. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Buy Or Sell Opportunity • Jul 08
Now 29% overvalued after recent price rise Over the last 90 days, the stock has risen 2.1% to CA$0.49. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Buy Or Sell Opportunity • Jun 04
Now 24% overvalued Over the last 90 days, the stock has fallen 9.8% to CA$0.46. The fair value is estimated to be CA$0.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only. New Risk • Feb 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (478% increase in shares outstanding). Revenue is less than US$1m (CA$1.4m revenue, or US$981k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$64.5m market cap, or US$45.3m). Board Change • Oct 04
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Ken Brownell was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Oct 03
PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada. PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire Pharmacy business including land and buildings located in Atlanfic Canada for CAD 15.4 million on September 24, 2024. A cash consideration of CAD 15.18 million will be paid by PharmaCorp Rx Inc. The consideration consists of common equity of PharmaCorp Rx Inc. having a value of CAD 0.2 million to be issued for assets of Pharmacy business including land and buildings located in Atlanfic Canada. As part of consideration, CAD 15.38 million is paid towards assets of Pharmacy business including land and buildings located in Atlanfic Canada.
For the period ending April 30, 2024, Pharmacy business including land and buildings located in Atlanfic Canada reported total revenue of CAD 10.36 million, net income of CAD 0.44 million, net assets of CAD 2.21 million and total debt of CAD 1.01 million.
The transaction is subject to satisfaction of customary closing conditions, including the conditional acceptance of the TSX Venture Exchange. The expected completion of the transaction is October 1, 2024.
PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada on October 2, 2024. Ankündigung • Sep 05
PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada. PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transaction is that the Vendors will retain a 10% interest in the Acquired Pharmacy and have agreed to continue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist.
The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024.
PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada on September 3, 2024. Ankündigung • Aug 23
PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million. PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transacfion is that the Vendors will retain a 10% interest in the Acquired Pharmacy, and have agreed to confinue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist.
The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024. Ankündigung • Aug 22
PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024 PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024. New Risk • Aug 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 366% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (366% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$43.8m market cap, or US$31.6m). Board Change • Jul 23
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Glenn Fradette is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Ankündigung • May 29
Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy. Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy on May 27, 2024. Ankündigung • Nov 17
Proton Capital Corp., Annual General Meeting, Jan 22, 2024 Proton Capital Corp., Annual General Meeting, Jan 22, 2024.